Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
somatropin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| somatropin | DRUG | 0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years |
Inclusion Criteria: * Pre-pubertal children of either sex presenting with severe early onset intrauterine growth retardation (I.U.G.R.) * Height Less Than or Equal to -3 SD Exclusion Criteria: * Age less than 3 years The above information is not intended to contain all considerations relevant to...
Somatropin is used for fetal growth retardation, specifically in the treatment of severe early onset intrauterine growth retardation in pre-pubertal children. It is being investigated as a treatment for this condition in a clinical trial setting.
Somatropin is being developed by Sanofi, a biopharmaceutical company. Sanofi is conducting clinical trials to evaluate the drug's efficacy and safety in treating fetal growth retardation.
Somatropin is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved for use and is still being studied in clinical trials to assess its safety and effectiveness.
Somatropin is being studied in a Phase 3 clinical trial with the identifier NCT00452491. This trial is titled 'MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children' and has been completed.
The clinical trial for somatropin is studying its use in treating fetal growth retardation in pre-pubertal children. The trial enrolled 306 participants in France, with a minimum age of 3 years, and included both males and females.